{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:42:05Z","timestamp":1791999725876,"version":"4.4.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82405510"],"award-info":[{"award-number":["No.82405510"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07720-2","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:26:43Z","timestamp":1768552003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recent advances and future prospects of immunotherapeutic approaches in prostate cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Na","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanming","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"1","key":"7720_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025[J]. Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"Cancer J Clin"},{"issue":"8","key":"7720_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.5694\/mja2.51722","volume":"217","author":"IS Williams","year":"2022","unstructured":"Williams IS, McVey A, Perera S, et al. Modern paradigms for prostate cancer detection and management[J]. Med J Australia. 2022;217(8):424\u201333.","journal-title":"Med J Australia"},{"issue":"2","key":"7720_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, Van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer. Part II-2024 update: treatment of relapsing and metastatic prostate Cancer[J]. Eur Urol. 2024;86(2):164\u201382.","journal-title":"Eur Urol"},{"issue":"5","key":"7720_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14712598.2022.2027904","volume":"22","author":"I Mitsogiannis","year":"2022","unstructured":"Mitsogiannis I, Tzelves L, Dellis A, et al. Prostate cancer immunotherapy[J]. Expert Opin Biol Ther. 2022;22(5):577\u201390.","journal-title":"Expert Opin Biol Ther"},{"key":"7720_CR5","doi-asserted-by":"publisher","first-page":"217155","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang LF, Guo YL. Advances in and prospects of immunotherapy for prostate cancer [J]. Cancer Lett. 2024;601:217155.","journal-title":"Cancer Lett"},{"key":"7720_CR6","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou LQ, He SM. Cancer immunotherapies: advances and bottlenecks[J]. Front Immunol. 2023;14:1212476.","journal-title":"Front Immunol"},{"issue":"22","key":"7720_CR7","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-17-0019","volume":"23","author":"M Bilusic","year":"2017","unstructured":"Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and Hopes[J]. Clin Cancer Research: Official J Am Association Cancer Res. 2017;23(22):6764\u201370.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"10","key":"7720_CR8","doi-asserted-by":"publisher","first-page":"101199","DOI":"10.1016\/j.xcrm.2023.101199","volume":"4","author":"D Sridaran","year":"2023","unstructured":"Sridaran D, Bradshaw E, DeSelm C, et al. Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach[J]. Cell Rep Med. 2023;4(10):101199.","journal-title":"Cell Rep Med"},{"issue":"1","key":"7720_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40779-024-00526-7","volume":"11","author":"D-C Feng","year":"2024","unstructured":"Feng D-C, Zhu W-Z, Wang J, et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy[J]. Military Med Res. 2024;11(1):21.","journal-title":"Military Med Res"},{"issue":"1","key":"7720_CR10","doi-asserted-by":"publisher","first-page":"15597","DOI":"10.1038\/s41598-023-42858-9","volume":"13","author":"XY Wen","year":"2023","unstructured":"Wen XY, Wang RY, Yu B, et al. Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer[J]. Sci Rep. 2023;13(1):15597.","journal-title":"Sci Rep"},{"issue":"8","key":"7720_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.urolonc.2018.10.011","volume":"37","author":"CS Jansen","year":"2019","unstructured":"Jansen CS, Prokhnevska N, Kissick HT. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer[J]. Urol Oncol. 2019;37(8):543\u201355.","journal-title":"Urol Oncol"},{"issue":"11","key":"7720_CR12","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","volume":"41","author":"JE Hawley","year":"2023","unstructured":"Hawley JE, Obradovic AZ, Dallos MC, et al. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer[J]. Cancer Cell. 2023;41(11):1972\u2013e19885.","journal-title":"Cancer Cell"},{"issue":"1","key":"7720_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1200\/JCO.2016.70.4791","volume":"35","author":"W Kim","year":"2017","unstructured":"Kim W, Fong L. Can prostate cancer really respond to Immunotherapy?[J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35(1):4\u20135.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"5","key":"7720_CR14","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00345-020-03497-1","volume":"39","author":"I Tsaur","year":"2021","unstructured":"Tsaur I, Brandt MP, Juengel E, et al. Immunotherapy in prostate cancer: new horizon of hurdles and hopes[J]. World J Urol. 2021;39(5):1387\u2013403.","journal-title":"World J Urol"},{"key":"7720_CR15","doi-asserted-by":"crossref","unstructured":"Maselli FM, Giuliani F, Laface C, et al. Immunotherapy in prostate cancer: state of art and new therapeutic perspectives. Curr Oncol (Toronto). 2023;30(6):5769\u20135794.","DOI":"10.3390\/curroncol30060432"},{"issue":"5","key":"7720_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer [J]. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"key":"7720_CR17","doi-asserted-by":"crossref","unstructured":"Y LM. Y, A M, Emerging immunotherapy approaches for treating prostate cancer [J]. Int J Mol Sci. 2023;24(18).","DOI":"10.3390\/ijms241814347"},{"issue":"12","key":"7720_CR18","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1586\/14760584.2015.1099437","volume":"14","author":"XX Wei","year":"2015","unstructured":"Wei XX, Fong L, Small EJ. Prostate cancer immunotherapy with Sipuleucel-T: current standards and future Directions[J]. Expert Rev Vaccines. 2015;14(12):1529\u201341.","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"7720_CR19","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/vaccines12121384","volume":"12","author":"WH Zhou","year":"2024","unstructured":"Zhou WH, Lu XJ, Tian F, et al. Vaccine therapies for prostate cancer: current status and future Outlook[J]. Vaccines. 2024;12(12):1384.","journal-title":"Vaccines"},{"key":"7720_CR20","doi-asserted-by":"crossref","unstructured":"I R, Dg AM. M. Vaccines as treatments for prostate cancer [J]. Nat Rev Urol. 2023;20(9).","DOI":"10.1038\/s41585-023-00739-w"},{"issue":"20","key":"7720_CR21","doi-asserted-by":"publisher","first-page":"e70294","DOI":"10.1002\/cam4.70294","volume":"13","author":"JD He","year":"2024","unstructured":"He JD, Wu JL, Li ZA, et al. Immunotherapy vaccines for prostate cancer Treatment[J]. Cancer Med. 2024;13(20):e70294.","journal-title":"Cancer Med"},{"issue":"2","key":"7720_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.eururo.2011.09.020","volume":"61","author":"S Joniau","year":"2012","unstructured":"Joniau S, Abrahamsson P-A, Bellmunt J, et al. Current vaccination strategies for prostate cancer[J]. Eur Urol. 2012;61(2):290\u2013306.","journal-title":"Eur Urol"},{"issue":"1","key":"7720_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy[J]. Cell Res. 2017;27(1):74\u201395.","journal-title":"Cell Res"},{"issue":"6 Pt 2","key":"7720_CR24","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1097\/01.ju.0000144211.51111.e4","volume":"172","author":"H Ragde","year":"2004","unstructured":"Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer[J]. J Urol. 2004;172(6 Pt 2):2532\u20138.","journal-title":"J Urol"},{"issue":"8","key":"7720_CR25","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1080\/08820139.2022.2109486","volume":"51","author":"CM Fu","year":"2022","unstructured":"Fu CM, Ma TL, Zhou L, et al. Dendritic Cell-Based vaccines against cancer: Challenges, advances and future Opportunities[J]. Immunol Investig. 2022;51(8):2133\u201358.","journal-title":"Immunol Investig"},{"issue":"11","key":"7720_CR26","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine[J]. Clin Cancer Research: Official J Am Association Cancer Res. 2011;17(11):3520\u20136.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"4","key":"7720_CR27","doi-asserted-by":"publisher","first-page":"e1107698","DOI":"10.1080\/2162402X.2015.1107698","volume":"5","author":"JL Gulley","year":"2016","unstructured":"Gulley JL, Mulders P, Albers P, et al. Perspectives on sipuleucel-T: its role in the prostate cancer treatment paradigm[J]. Oncoimmunology. 2016;5(4):e1107698.","journal-title":"Oncoimmunology"},{"issue":"6","key":"7720_CR28","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/jnci\/djaa021","volume":"112","author":"RA Madan","year":"2020","unstructured":"Madan RA, Antonarakis ES, Drake CG, et al. Putting the pieces together: completing the mechanism of action Jigsaw for Sipuleucel-T[J]. J Natl Cancer Inst. 2020;112(6):562\u201373.","journal-title":"J Natl Cancer Inst"},{"key":"7720_CR29","doi-asserted-by":"crossref","unstructured":"Paller CJ, Antonarakis ES. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. Hum Vaccin Immunother. 2012;8:509\u2013519.","DOI":"10.4161\/hv.18860"},{"issue":"19","key":"7720_CR30","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","volume":"24","author":"EJ Small","year":"2006","unstructured":"Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of Immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer[J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2006;24(19):3089\u201394.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"13","key":"7720_CR31","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1158\/1078-0432.CCR-22-3832","volume":"29","author":"ES Antonarakis","year":"2023","unstructured":"Antonarakis ES, Subudhi SK, Pieczonka CM, et al. Combination treatment with Sipuleucel-T and abiraterone acetate or enzalutamide for metastatic Castration-Resistant prostate cancer: STAMP and STRIDE Trials[J]. Clin Cancer Research: Official J Am Association Cancer Res. 2023;29(13):2426\u201334.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"4","key":"7720_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","volume":"8","author":"NJ Vogelzang","year":"2022","unstructured":"Vogelzang NJ, Beer TM, Gerritsen W, et al. Efficacy and safety of autologous dendritic Cell-Based Immunotherapy, Docetaxel, and prednisone vs placebo in patients with metastatic Castration-Resistant prostate cancer: the VIABLE phase 3 randomized clinical Trial[J]. JAMA Oncol. 2022;8(4):546\u201352.","journal-title":"JAMA Oncol"},{"issue":"7","key":"7720_CR33","first-page":"1498","volume":"13","author":"S Hawlina","year":"2023","unstructured":"Hawlina S, Zorec R, Chowdhury HH. Potential of personalized dendritic Cell-Based Immunohybridoma vaccines to treat prostate Cancer[J]. Life (Basel Switzerland). 2023;13(7):1498.","journal-title":"Life (Basel Switzerland)"},{"issue":"8","key":"7720_CR34","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.biotechadv.2015.10.013","volume":"33","author":"L Peres","year":"2015","unstructured":"Peres L, de P, Da Luz FAC, Pultz B dos. Peptide vaccines in breast cancer: the immunological basis for clinical response[J]. Biotechnol Adv. 2015;33(8):1868\u201377.","journal-title":"Biotechnol Adv"},{"issue":"3","key":"7720_CR35","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/cas.13506","volume":"109","author":"W Obara","year":"2018","unstructured":"Obara W, Kanehira M, Katagiri T, et al. Present status and future perspective of peptide-based vaccine therapy for urological cancer[J]. Cancer Sci. 2018;109(3):550\u20139.","journal-title":"Cancer Sci"},{"issue":"5","key":"7720_CR36","doi-asserted-by":"publisher","first-page":"e004345","DOI":"10.1136\/jitc-2021-004345","volume":"10","author":"EB Ellingsen","year":"2022","unstructured":"Ellingsen EB, Aamdal E, Guren T, et al. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials[J]. J Immunother Cancer. 2022;10(5):e004345.","journal-title":"J Immunother Cancer"},{"key":"7720_CR37","doi-asserted-by":"crossref","unstructured":"Matsueda S, Takedatsu H, Yao A, et al. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles [J]. Clin Cancer Res: an Off J Am Assoc Cancer Res. 2005;11(19 Pt 1):6933\u20136943.","DOI":"10.1158\/1078-0432.CCR-05-0682"},{"issue":"5","key":"7720_CR38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00262-020-02498-8","volume":"69","author":"M Noguchi","year":"2020","unstructured":"Noguchi M, Arai G, Egawa S, et al. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial[J]. Cancer Immunol Immunotherapy: CII. 2020;69(5):847\u201357.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"key":"7720_CR39","doi-asserted-by":"publisher","first-page":"1000681","DOI":"10.3389\/fimmu.2022.1000681","volume":"13","author":"JW Shou","year":"2022","unstructured":"Shou JW, Mo F, Zhang SS, et al. Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: promising modality for future cancer immunotherapy[J]. Front Immunol. 2022;13:1000681.","journal-title":"Front Immunol"},{"key":"7720_CR40","doi-asserted-by":"crossref","unstructured":"Zahm CD, Colluru VT, McNeel DG. DNA vaccines for prostate cancer. Pharmacol Ther. 2017;174:27\u201342.","DOI":"10.1016\/j.pharmthera.2017.02.016"},{"key":"7720_CR41","doi-asserted-by":"publisher","first-page":"104643","DOI":"10.1016\/j.critrevonc.2025.104643","volume":"208","author":"GJ Lin","year":"2025","unstructured":"Lin GJ, Elkashif A, Saha CYNK, et al. Key considerations for a prostate cancer mRNA vaccine[J]. Crit Rev Oncol\/Hematol. 2025;208:104643.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"7720_CR42","doi-asserted-by":"crossref","unstructured":"Yaremenko AV, Khan MM, Zhen XY, et al. Clinical advances of mRNA vaccines for cancer immunotherapy. Med (N Y). 2025;6:100562.","DOI":"10.1016\/j.medj.2024.11.015"},{"issue":"7","key":"7720_CR43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1586\/erv.10.64","volume":"9","author":"S Alam","year":"2010","unstructured":"Alam S, McNeel DG. DNA vaccines for the treatment of prostate cancer[J]. Expert Rev Vaccines. 2010;9(7):731\u201345.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"7720_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.vaccine.2005.07.074","volume":"24","author":"LE Johnson","year":"2006","unstructured":"Johnson LE, Frye TP, Arnot AR, et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)[J]. Vaccine. 2006;24(3):293\u2013303.","journal-title":"Vaccine"},{"issue":"36","key":"7720_CR45","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1200\/JCO.19.01701","volume":"37","author":"DG McNeel","year":"2019","unstructured":"McNeel DG, Eickhoff JC, Johnson LE, et al. Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP [MVI-816]) in patients with Progressive, Nonmetastatic, Castration-Sensitive prostate Cancer[J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(36):3507\u201317.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"7720_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40425-018-0333-y","volume":"6","author":"E Wargowski","year":"2018","unstructured":"Wargowski E, Johnson LE, Eickhoff JC, et al. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine[J]. J Immunother Cancer. 2018;6(1):21.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"7720_CR47","doi-asserted-by":"publisher","first-page":"e008067","DOI":"10.1136\/jitc-2023-008067","volume":"11","author":"DG McNeel","year":"2023","unstructured":"McNeel DG, Emamekhoo H, Eickhoff JC, et al. Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer[J]. J Immunother Cancer. 2023;11(12):e008067.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"7720_CR48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-021-01452-1","volume":"20","author":"XN Zheng","year":"2021","unstructured":"Zheng XN, Xu H, Yi XYL, et al. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine[J]. Mol Cancer. 2021;20(1):160.","journal-title":"Mol Cancer"},{"issue":"1","key":"7720_CR49","doi-asserted-by":"publisher","first-page":"2373526","DOI":"10.1080\/2162402X.2024.2373526","volume":"13","author":"Z Xu","year":"2024","unstructured":"Xu Z, Xiao Z-X, Wang J, et al. Novel mRNA adjuvant immuner enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity[J]. Oncoimmunology. 2024;13(1):2373526.","journal-title":"Oncoimmunology"},{"key":"7720_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","volume":"3","author":"H K\u00fcbler","year":"2015","unstructured":"K\u00fcbler H, Scheel B, Gnad-Vogt U, et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study[J]. J Immunother Cancer. 2015;3:26.","journal-title":"J Immunother Cancer"},{"key":"7720_CR51","doi-asserted-by":"crossref","unstructured":"Rausch S, Schwentner C, Stenzl A, et al. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer [J]. Hum Vaccin Immunothe. 2014;10(11):3146\u201352.","DOI":"10.4161\/hv.29553"},{"issue":"18","key":"7720_CR52","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.7150\/thno.100555","volume":"14","author":"SB Hansen","year":"2024","unstructured":"Hansen SB, Unal B, Kuzu OF, et al. Immunological facets of prostate cancer and the potential of immune checkpoint Inhibition in disease management[J]. Theranostics. 2024;14(18):6913\u201334.","journal-title":"Theranostics"},{"issue":"4","key":"7720_CR53","first-page":"210","volume":"10","author":"I Wang","year":"2022","unstructured":"Wang I, Song LK, Wang BY, et al. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy[J]. Am J Clin Experimental Urol. 2022;10(4):210\u201333.","journal-title":"Am J Clin Experimental Urol"},{"issue":"6","key":"7720_CR54","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.ymthe.2021.04.029","volume":"29","author":"YC Xu","year":"2021","unstructured":"Xu YC, Song GD, Xie SD, et al. The roles of PD-1\/PD-L1 in the prognosis and immunotherapy of prostate cancer[J]. Mol Therapy: J Am Soc Gene Therapy. 2021;29(6):1958\u201369.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"5","key":"7720_CR55","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.eururo.2024.04.026","volume":"86","author":"N Kl\u00fcmper","year":"2024","unstructured":"Kl\u00fcmper N, Gr\u00fcnwald V, Hartmann A, et al. The role of microsatellite Instability\/DNA mismatch repair deficiency and tumor mutational burden as biomarkers in predicting response to immunotherapy in Castration-resistant prostate Cancer[J]. Eur Urol. 2024;86(5):388\u201390.","journal-title":"Eur Urol"},{"issue":"8","key":"7720_CR56","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.3390\/ijms22084109","volume":"22","author":"MM Kgatle","year":"2021","unstructured":"Kgatle MM, Boshomane TMG, Lawal IO, et al. Immune Checkpoints, inhibitors and radionuclides in prostate cancer: promising combinatorial therapy Approach[J]. Int J Mol Sci. 2021;22(8):4109.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"7720_CR57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang Y-J, Piha-Paul SA, et al. T-Cell-Inflamed Gene-Expression Profile, programmed death ligand 1 Expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028[J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(4):318\u201327.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"5","key":"7720_CR58","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for Treatment-Refractory metastatic Castration-Resistant prostate cancer: Multicohort, Open-Label phase II KEYNOTE-199 Study[J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2020;38(5):395\u2013405.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"14","key":"7720_CR59","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak DP, Ratta R, Matsubara N, et al. Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial[J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2025;43(14):1638\u201349.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"12","key":"7720_CR60","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1158\/1078-0432.CCR-20-1981","volume":"27","author":"DP Petrylak","year":"2021","unstructured":"Petrylak DP, Loriot Y, Shaffer DR, et al. Safety and clinical activity of Atezolizumab in patients with metastatic Castration-Resistant prostate cancer: A phase I Study[J]. Clin Cancer Research: Official J Am Association Cancer Res. 2021;27(12):3360\u20139.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"6","key":"7720_CR61","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","volume":"78","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Drake CG, Beer TM, et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic Castration-resistant prostate cancer identifies an excess of Long-term Survivors[J]. Eur Urol. 2020;78(6):822\u201330.","journal-title":"Eur Urol"},{"issue":"537","key":"7720_CR62","doi-asserted-by":"publisher","first-page":"eaaz3577","DOI":"10.1126\/scitranslmed.aaz3577","volume":"12","author":"SK Subudhi","year":"2020","unstructured":"Subudhi SK, Vence L, Zhao H, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer[J]. Sci Transl Med. 2020;12(537):eaaz3577.","journal-title":"Sci Transl Med"},{"issue":"12","key":"7720_CR63","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","volume":"35","author":"S Van Wilpe","year":"2024","unstructured":"Van Wilpe S, Kloots ISH, Slootbeek PHJ, et al. Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial[J]. Annals Oncology: Official J Eur Soc Med Oncol. 2024;35(12):1126\u201337.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"9","key":"7720_CR64","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41585-021-00488-8","volume":"18","author":"P Wolf","year":"2021","unstructured":"Wolf P, Alzubi J, Gratzke C, et al. The potential of CAR T cell therapy for prostate cancer[J]. Nat Rev Urol. 2021;18(9):556\u201371.","journal-title":"Nat Rev Urol"},{"key":"7720_CR65","first-page":"22","volume-title":"The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review[J]","author":"OM Saleh","year":"2022","unstructured":"Saleh OM, Albakri KA, Alabdallat YJ, et al. The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review[J]. Volume 27. Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals; 2022. pp. 22\u201334. 1."},{"issue":"1","key":"7720_CR66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","volume":"25","author":"FJ Wang","year":"2022","unstructured":"Wang FJ, Li ZF, Feng XQ, et al. Advances in PSMA-targeted therapy for prostate cancer[J]. Prostate Cancer Prostatic Dis. 2022;25(1):11\u201326.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"19","key":"7720_CR67","doi-asserted-by":"publisher","first-page":"9080","DOI":"10.1158\/0008-5472.CAN-05-0436","volume":"65","author":"TPF Gade","year":"2005","unstructured":"Gade TPF, Hassen W, Santos E, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes[J]. Cancer Res. 2005;65(19):9080\u20138.","journal-title":"Cancer Res"},{"issue":"10","key":"7720_CR68","doi-asserted-by":"publisher","first-page":"e109427","DOI":"10.1371\/journal.pone.0109427","volume":"9","author":"G Zuccolotto","year":"2014","unstructured":"Zuccolotto G, Fracasso G, Merlo A, et al. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models[J]. PLoS ONE. 2014;9(10):e109427.","journal-title":"PLoS ONE"},{"issue":"7","key":"7720_CR69","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer Eradication[J]. Mol Therapy: J Am Soc Gene Therapy. 2018;26(7):1855\u201366.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"4","key":"7720_CR70","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung I-Y, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial [J]. Nat Med. 2022;28(4):724\u201334.","journal-title":"Nat Med"},{"issue":"15suppl","key":"7720_CR71","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.2021.39.15_suppl.2534","volume":"39","author":"MH Carabasi","year":"2021","unstructured":"Carabasi MH, McKean M, Stein MN, et al. PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.[J]. J Clin Oncol. 2021;39(15suppl):2534\u20132534.","journal-title":"J Clin Oncol"},{"issue":"6suppl","key":"7720_CR72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1200\/JCO.2022.40.6_suppl.098","volume":"40","author":"SF Slovin","year":"2022","unstructured":"Slovin SF, Dorff TB, Falchook GS, et al. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).[J]. J Clin Oncol. 2022;40(6suppl):98\u201398.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7720_CR73","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","volume":"19","author":"Z Gu","year":"2000","unstructured":"Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer[J]. Oncogene. 2000;19(10):1288\u201396.","journal-title":"Oncogene"},{"key":"7720_CR74","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/OTT.S185556","volume":"12","author":"HY Yu","year":"2019","unstructured":"Yu HY, Pan J, Guo ZC, et al. CART cell therapy for prostate cancer: status and promise[J]. OncoTargets Therapy. 2019;12:391\u20135.","journal-title":"OncoTargets Therapy"},{"issue":"2","key":"7720_CR75","doi-asserted-by":"publisher","first-page":"e1380764","DOI":"10.1080\/2162402X.2017.1380764","volume":"7","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Gerdts EA, Tilakawardane D, et al. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA\u2009+\u2009metastatic prostate cancer[J]. Oncoimmunology. 2018;7(2):e1380764.","journal-title":"Oncoimmunology"},{"issue":"1","key":"7720_CR76","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.1038\/s41467-024-53220-6","volume":"15","author":"MN Stein","year":"2024","unstructured":"Stein MN, Dumbrava EE, Teply BA, et al. PSCA-targeted BPX-601 CAR T cells with Pharmacological activation by Rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial[J]. Nat Commun. 2024;15(1):10743.","journal-title":"Nat Commun"},{"issue":"6","key":"7720_CR77","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff TB, Blanchard MS, Adkins LN, et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial[J]. Nat Med. 2024;30(6):1636\u201344.","journal-title":"Nat Med"},{"issue":"14","key":"7720_CR78","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.32909","volume":"126","author":"H Einsele","year":"2020","unstructured":"Einsele H, Borghaei H, Orlowski RZ, et al. The bite (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types[J]. Cancer. 2020;126(14):3192\u2013201.","journal-title":"Cancer"},{"issue":"1","key":"7720_CR79","doi-asserted-by":"publisher","first-page":"2356820","DOI":"10.1080\/15384047.2024.2356820","volume":"25","author":"J Palecki","year":"2024","unstructured":"Palecki J, Bhasin A, Bernstein A, et al. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer[J]. Cancer Biol Ther. 2024;25(1):2356820.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"7720_CR80","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/cancers13030549","volume":"13","author":"JS Heitmann","year":"2021","unstructured":"Heitmann JS, Pfluegler M, Jung G, et al. Bispecific antibodies in prostate cancer therapy: current status and Perspectives[J]. Cancers. 2021;13(3):549.","journal-title":"Cancers"},{"issue":"12","key":"7720_CR81","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1158\/1535-7163.MCT-12-0042","volume":"11","author":"M Friedrich","year":"2012","unstructured":"Friedrich M, Raum T, Lutterbuese R, et al. Regression of human prostate cancer xenografts in mice by AMG 212\/BAY2010112, a novel PSMA\/CD3-Bispecific bite antibody cross-reactive with non-human primate antigens[J]. Mol Cancer Ther. 2012;11(12):2664\u201373.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"7720_CR82","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/imr.12393","volume":"270","author":"M Klinger","year":"2016","unstructured":"Klinger M, Benjamin J, Kischel R, et al. Harnessing T cells to fight cancer with BiTE\u00ae antibody constructs\u2014past developments and future directions[J]. Immunol Rev. 2016;270(1):193\u2013208.","journal-title":"Immunol Rev"},{"issue":"2","key":"7720_CR83","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"H-D Hummel","year":"2021","unstructured":"Hummel H-D, Kufer P, Gr\u00fcllich C, et al. Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings[J]. Immunotherapy. 2021;13(2):125\u201341.","journal-title":"Immunotherapy"},{"key":"7720_CR84","doi-asserted-by":"publisher","first-page":"1261070","DOI":"10.3389\/fimmu.2023.1261070","volume":"14","author":"HL Penny","year":"2023","unstructured":"Penny HL, Hainline K, Theoharis N, et al. Characterization and root cause analysis of immunogenicity to Pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy[J]. Front Immunol. 2023;14:1261070.","journal-title":"Front Immunol"},{"issue":"10","key":"7720_CR85","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","volume":"27","author":"P Deegen","year":"2021","unstructured":"Deegen P, Thomas O, Nolan-Stevaux O, et al. The PSMA-targeting Half-life extended bite therapy AMG 160 has potent antitumor activity in preclinical models of metastatic Castration-resistant prostate Cancer[J]. Clin Cancer Research: Official J Am Association Cancer Res. 2021;27(10):2928\u201337.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"7720_CR86","doi-asserted-by":"crossref","unstructured":"Paweletz KL, Li S, Bailis JM, et al. Combination of AMG 160, a PSMA \u00d7 CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa). J Clin Oncol. 2020;38 (6_suppl):155.","DOI":"10.1200\/JCO.2020.38.6_suppl.155"},{"issue":"9","key":"7720_CR87","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41585-025-01014-w","volume":"22","author":"C Boixareu","year":"2025","unstructured":"Boixareu C, Taha T, Venkadakrishnan VB, et al. Targeting the tumour cell surface in advanced prostate cancer[J]. Nat Rev Urol. 2025;22(9):569\u201389.","journal-title":"Nat Rev Urol"},{"issue":"8","key":"7720_CR88","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.trecan.2025.05.007","volume":"11","author":"R Singh","year":"2025","unstructured":"Singh R, Kyte JA. STEAP1: a promising target in prostate cancer therapy[J]. Trends Cancer. 2025;11(8):722\u20135.","journal-title":"Trends Cancer"},{"issue":"1","key":"7720_CR89","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly WK, Danila DC, Lin C-C, et al. Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2\u2009+\u20091 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study[J]. Cancer Discov. 2024;14(1):76\u201389.","journal-title":"Cancer Discov"},{"issue":"1","key":"7720_CR90","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2159-8290.CD-23-0984","volume":"14","author":"O Nolan-Stevaux","year":"2024","unstructured":"Nolan-Stevaux O, Li C, Liang L, et al. AMG 509 (xaluritamig), an anti-STEAP1 XmAb 2\u2009+\u20091 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer[J]. Cancer Discov. 2024;14(1):90\u2013103.","journal-title":"Cancer Discov"},{"key":"7720_CR91","doi-asserted-by":"crossref","unstructured":"Tran B, Courtney KD, Sokolova A, et al. A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy[J]. J Clin Oncol, 2025, 43(5_suppl).","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS435"},{"key":"7720_CR92","unstructured":"Morris MJ, Horvath L, Gr\u00fcnwald V, et al. Trial in progress (XALute): phase 3 study of xaluritamig vs investigator\u2019s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC) [J]. J Clin Oncol; 2025."},{"key":"7720_CR93","doi-asserted-by":"crossref","unstructured":"Baldini C, Vinceneux A, Robbrecht DGJ, et al. Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC) [J]. J Clin Oncol. 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.5017"},{"issue":"22","key":"7720_CR94","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO-25-00678","volume":"43","author":"MN Stein","year":"2025","unstructured":"Stein MN, Vinceneux A, Robbrecht D, et al. Pasritamig, a first-in-class, bispecific T-cell engager targeting human Kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study[J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2025;43(22):2515\u201326.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"7720_CR95","unstructured":"Wheeler TM, Sylvester J, Schroeder T, et al. Phase 3, randomized, placebo-controlled clinical trial of CAN-2409\u2009+\u2009prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer [J]. J Clin Oncol; 2025."},{"issue":"7","key":"7720_CR96","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"Y-M Wu","year":"2018","unstructured":"Wu Y-M, Cie\u015blik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct Immunogenic class of advanced prostate cancer[J]. Cell. 2018;173(7):1770\u2013e178214.","journal-title":"Cell"},{"key":"7720_CR97","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1200\/PO.20.00080","volume":"4","author":"BA McGregor","year":"2020","unstructured":"McGregor BA, Wei XX. CDK12 loss in prostate cancer imparts poor prognosis and limited susceptibility to immune checkpoint inhibition[J]. JCO Precision Oncol. 2020;4:367\u20139.","journal-title":"JCO Precision Oncol"},{"issue":"18","key":"7720_CR98","doi-asserted-by":"publisher","first-page":"e193745","DOI":"10.1172\/JCI193745","volume":"135","author":"Y Bao","year":"2025","unstructured":"Bao Y, Chang Y, Tien JC-Y, et al. CDK12\/13 inactivation triggers STING-mediated antitumor immunity in preclinical models[J]. J Clin Invest. 2025;135(18):e193745.","journal-title":"J Clin Invest"},{"issue":"10","key":"7720_CR99","doi-asserted-by":"publisher","first-page":"101758","DOI":"10.1016\/j.xcrm.2024.101758","volume":"5","author":"JC-Y Tien","year":"2024","unstructured":"Tien JC-Y, Luo J, Chang Y, et al. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13[J]. Cell Rep Med. 2024;5(10):101758.","journal-title":"Cell Rep Med"},{"issue":"1","key":"7720_CR100","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","volume":"74","author":"I Bajrami","year":"2014","unstructured":"Bajrami I, Frankum JR, Konde A, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity[J]. Cancer Res. 2014;74(1):287\u201397.","journal-title":"Cancer Res"},{"issue":"8","key":"7720_CR101","doi-asserted-by":"publisher","first-page":"e004761","DOI":"10.1136\/jitc-2022-004761","volume":"10","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Retz M, Petrylak DP, et al. Nivolumab plus Rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 checkmate 9KD trial[J]. J Immunother Cancer. 2022;10(8):e004761.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"7720_CR102","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/cancers17040682","volume":"17","author":"T Borbiev","year":"2025","unstructured":"Borbiev T, Babcock K, Sinopole K, et al. Ancestry-specific DNA damage repair gene mutations and prostate cancer[J]. Cancers. 2025;17(4):682.","journal-title":"Cancers"},{"key":"7720_CR103","doi-asserted-by":"crossref","unstructured":"Sciarra A, Santarelli V, Santodirocco L, et al. Is it time to anticipate the use of PARP inhibition in prostate cancer patients? [J]. Curr Oncol. 2023;30(9):8054\u201367.","DOI":"10.3390\/curroncol30090584"},{"issue":"1","key":"7720_CR104","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1186\/s12967-023-04743-x","volume":"21","author":"M Li","year":"2023","unstructured":"Li M, Bai G, Cen Y, et al. Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS\/STING\/IRF3 pathway[J]. J Translational Med. 2023;21(1):884.","journal-title":"J Translational Med"},{"issue":"1","key":"7720_CR105","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14756366.2020.1754812","volume":"35","author":"Y Song","year":"2020","unstructured":"Song Y, Park SY, Wu Z, et al. Hybrid inhibitors of DNA and HDACs remarkably enhance cytotoxicity in leukaemia cells[J]. J Enzyme Inhib Med Chem. 2020;35(1):1069\u201379.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"7720_CR106","doi-asserted-by":"crossref","unstructured":"Es A, Sh P, Jc G, et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial [J]. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41(22).","DOI":"10.1200\/JCO.23.00233"},{"issue":"4","key":"7720_CR107","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamaoncol.2023.6817","volume":"10","author":"PD Zang","year":"2024","unstructured":"Zang PD, Chawla NS, Barragan-Carrillo R, et al. Tumor mutational burden in metastatic castration-resistant prostate cancer and response to checkpoint inhibition[J]. JAMA Oncol. 2024;10(4):531\u20132.","journal-title":"JAMA Oncol"},{"issue":"1","key":"7720_CR108","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s43856-024-00687-5","volume":"4","author":"RM Barnett","year":"2024","unstructured":"Barnett RM, Jang A, Lanka S, et al. Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers[J]. Commun Med. 2024;4(1):256\u201363.","journal-title":"Commun Med"},{"issue":"17","key":"7720_CR109","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","volume":"30","author":"AT Lenis","year":"2024","unstructured":"Lenis AT, Ravichandran V, Brown S. Microsatellite Instability, tumor mutational Burden, and response to immune checkpoint Blockade in patients with prostate Cancer[J]. Clin Cancer Research: Official J Am Association Cancer Res. 2024;30(17):3894\u2013903.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"1","key":"7720_CR110","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","volume":"18","author":"S Sun","year":"2025","unstructured":"Sun S, Liu L, Zhang J, et al. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives[J]. J Hematol Oncol. 2025;18(1):84.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"7720_CR111","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2011.11.009","volume":"61","author":"AJ Armstrong","year":"2012","unstructured":"Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer[J]. Eur Urol. 2012;61(3):549\u201359.","journal-title":"Eur Urol"},{"issue":"5","key":"7720_CR112","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.eururo.2019.04.005","volume":"76","author":"M Fraser","year":"2019","unstructured":"Fraser M. Separating the dreadful from the merely bad: towards prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer[J]. Eur Urol. 2019;76(5):572\u20133.","journal-title":"Eur Urol"},{"issue":"4","key":"7720_CR113","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint Blockade[J]. JAMA Oncol. 2019;5(4):471\u20138.","journal-title":"JAMA Oncol"},{"key":"7720_CR114","unstructured":"At L, V R. S B, Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cance [J]. Clin Cancer Res: Official J Am Association Cancer Res. 2024;30(17)."},{"key":"7720_CR115","doi-asserted-by":"publisher","first-page":"1544882","DOI":"10.3389\/fimmu.2025.1544882","volume":"16","author":"JZ Che","year":"2025","unstructured":"Che JZ, Liu YY, Liu YY, et al. The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise[J]. Front Immunol. 2025;16:1544882.","journal-title":"Front Immunol"},{"key":"7720_CR116","doi-asserted-by":"crossref","unstructured":"Yx LC, Ys X. W. Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota [J]. Mol Cancer. 2024;23(1).","DOI":"10.1186\/s12943-024-02137-1"},{"issue":"2","key":"7720_CR117","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/PAP.0000000000000422","volume":"31","author":"D Akhoundova","year":"2024","unstructured":"Akhoundova D, Francica P, Rottenberg S, et al. DNA damage response and mismatch repair gene defects in advanced and metastatic prostate cancer[J]. Adv Anat Pathol. 2024;31(2):61\u20139.","journal-title":"Adv Anat Pathol"},{"key":"7720_CR118","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12885-021-07942-1","volume":"21","author":"J Xiao","year":"2021","unstructured":"Xiao J, Li W, Huang Y, et al. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer[J]. BMC Cancer. 2021;21:282.","journal-title":"BMC Cancer"},{"issue":"10","key":"7720_CR119","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/cancers15102824","volume":"15","author":"M Shanshal","year":"2023","unstructured":"Shanshal M, Caimi PF, Adjei AA, et al. T-Cell engagers in solid Cancers\u2014Current landscape and future Directions[J]. Cancers. 2023;15(10):2824.","journal-title":"Cancers"},{"key":"7720_CR120","doi-asserted-by":"crossref","unstructured":"Spinazzola A, Iannantuono GM, Gulley JL, et al. Current landscape of T-cell engagers in early-phase clinical development in solid cancers [J]. Front Immunol. 2025;16.","DOI":"10.3389\/fimmu.2025.1665838"},{"key":"7720_CR121","doi-asserted-by":"crossref","unstructured":"Albayrak G, Wan PK-T, Fisher K, et al. T cell engagers: expanding horizons in oncology and beyond [J]. British Journal of Cancer. 2025:19.","DOI":"10.1038\/s41416-025-03125-y"},{"issue":"2","key":"7720_CR122","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","volume":"33","author":"S Zheng","year":"2025","unstructured":"Zheng S, Che X, Zhang K, et al. Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal[J]. Mol Therapy: J Am Soc Gene Therapy. 2025;33(2):688\u2013702.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"7720_CR123","doi-asserted-by":"crossref","unstructured":"Aj H, Lc C, Yy C. Navigating CAR-T cells through the solid-tumour microenvironment [J]. Nat Rev Drug Discov. 2021;20(7).","DOI":"10.1038\/s41573-021-00189-2"},{"issue":"1","key":"7720_CR124","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","volume":"22","author":"DVF Tauriello","year":"2022","unstructured":"Tauriello DVF, Sancho E, Batlle E. Overcoming TGF\u03b2-mediated immune evasion in cancer[J]. Nat Rev Cancer. 2022;22(1):25\u201344.","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07720-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:09:19Z","timestamp":1770772159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07720-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7720"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07720-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}